GPRC5D-targeted immunotherapies offer new hope for relapsed multiple myeloma, but tumors increasingly evade treatment through multimodal antigenic escape, challenging long-term control and therapy sequencing decisions.

Emerging research links interferon gamma signaling to drug resistance in acute myeloid leukemia, suggesting immune pathways influence relapse risk, therapy response, and future precision treatment strategies.

Insurance type influences access to high-quality poststroke care; dual-eligible and Medicare Advantage patients are less likely than traditional Medicare beneficiaries to receive top-rated skilled nursing or home health services.

Oral contraceptives may cause yeast infections, dryness, libido changes, spotting, breast tenderness, mood shifts, or rare blood clots, requiring counseling, monitoring, and personalized adjustments to maintain safety and adherence.

A five-minute screening questionnaire helps primary care identify patients at risk for endometriosis earlier, guiding timely treatment, counseling, and specialist referral to reduce years-long diagnostic delays.

Radionuclide-stimulated dynamic therapy activates light-sensitive drugs with radiopharmaceuticals to produce cancer-killing reactive oxygen species, reprogram tumor immunity, and overcome resistance in aggressive cancers.

Cesarean incision location and layered uterine closure significantly influence scar healing, affecting bleeding, infection risk, and future pregnancy complications such as uterine rupture, placenta accreta, and infertility.

Advances in endocrinology are introducing safer therapies and minimally invasive treatments for hormonal disorders, improving patient outcomes, reducing healthcare costs, and reshaping clinical approaches to endocrine care.

The FDA granted Priority Review to trastuzumab deruxtecan for high-risk HER2-positive early breast cancer with residual disease, signaling a potential new standard to reduce recurrence risk.

New CHEST guidance helps clinicians match severe asthma patients to targeted biologic therapies using biomarkers, aiming to reduce steroid dependence, prevent exacerbations, and improve long-term disease control.